2002, Number 4
<< Back Next >>
Ann Hepatol 2002; 1 (4)
Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies
Sookoian S, Castaño G
Language: English
References: 12
Page: 179-182
PDF size: 68.58 Kb.
Text Extraction
The most practical screening test for hepatitis C virus antibodies are second and third- generation enzyme immunoassays. We evaluated the usefulness of the third generation microparticle enzyme immunoassay (MEIA) in predicting HCV viraemia in anti-HCV positive patients. Serum samples from 106 patients with positive anti-HCV were obtained. To evaluate the diagnostic value of the MEIA test in predicting HCV viraemia, anti-HCV positive patients were categorized in two groups according to the presence or absence of serum HCV-RNA. Among the 106 patients, 26 had non detectable serum HCV-RNA and 80 had detectable HCV-RNA by PCR. The assay automatically calculates a result based on the ratio of sample rate to the cut-of rate for each sample and control (S/CO). When the means of S/CO values for patients with detectable and non detectable HCV-RNA were analyzed, a statistically significant difference was found, (79.3 SD 22.2
vs. 8.2 SD 6.4, respectively) (p 0.0001). We further analyzed the best cut-off value of the S/CO in differentiating viremic from non viremic patients. The S/CO value of 26 showed a sensitivity of 99% and a specificity off 96% in discriminating both categories of HCV infected patients. In conclusion, our data demonstrate that viremic HCV patients had higher S/CO values in the MEIA test in comparison with non viremic patients. Hence, this assay may be used to predict HCV viraemia in anti-HCV positive individuals.
REFERENCES
Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26(Suppl 1): 21S-8.
Tong MJ, El-Farra NS., Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1436-66.
Gretch D. National Institutes of Health Consensus Development Conference Panel Statement: Diagnostic test for Hepatitis C. Hepatology 1997; 26: 43S-47S.
Zaaijer HL, Cuypers HT, Reesink HW, Winkel IN, Gerken G, Lelie PN. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993; 34: 722-724.
Busch M, Wilber J, Johnson P, Tobler L, Evans C. Impact of specimen handling and storage on detection of hepatitis C virus RNA. Transfusion 1992; 32: 420-425.
Tung HD, Lu SN, Lee CM, Wang JH, Chen TM, Hung CH, Huang WS, et al. Antiviral treatment responses in patients with chronic hepatitis C virus infection evaluated by a third generation anti-hepatitis C virus assay. J Viral Hepat 2002; 9: 304-308.
Chomczynski SP, Sacchi N. Single step method of RNA isolation by guanidium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 1987; 162: 156-159.
Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
Perniola R, De Rinaldis C, Leo G. Third-generation assays for hepatitis C antibodies: a four-year study of pattern changes in patients with chronic and past infection. Panminerva Med 1999; 41(4): 291-4.
Lanotte P, Dubois F, Le Pogam S, Guerois C, Fimbel B, Bacq Y, Gruel Y, et al. The kinetics of antibodies against hepatitis C virus may predict viral clearance in exposed haemophiliacs. J Infect Dis 1998; 178(2): 556-9.
Kondili LA, Chionne P, Costantino A, Villano U, Lo Nove C, Pannozzo F, Mele A, et al. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut 2002; 50(5): 693-6.
Baumert TF, Wellnitz S, Aono S, Satoi J, Herlon D, Tilman gerlach J, Page GR, et al. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. Hepatology 2000; 32(3): 610-7.
Full text